Phase Ib proof-of-concept trial investigating the pharmacokinetics, pharmacodynamics and tolerability of CP 024, an intranasal formulation of somatropin, versus subcutaneously administered Omnitrope in healthy volunteers
Latest Information Update: 21 Nov 2013
At a glance
- Drugs Somatropin (Primary) ; Somatropin (Primary)
- Indications Somatotropin deficiency
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
- 21 Nov 2013 New trial record
- 12 Feb 2013 Status changed to completed, based on information in a Critical Pharmaceuticals media release.